Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SAR231893 DP1 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| SAR231893 (REGN668) Drug Product (DP) 1 | EXPERIMENTAL | SAR231893 (REGN668) Drug Product 1 in a single subcutaneous injection |
| SAR231893 (REGN668) Drug Product (DP) 2 | EXPERIMENTAL | SAR231893 (REGN668) Drug Product 2 in a single subcutaneous injection |
| Name | Type | Description |
|---|---|---|
| SAR231893 (REGN668) DP1 | BIOLOGICAL | Pharmaceutical form:solution Route of administration: subcutaneous |
| SAR231893 (REGN668) DP2 | BIOLOGICAL | Pharmaceutical form:solution Route of administration: subcutaneous |
Inclusion criteria: * Healthy male and female subjects between 18 and 45 years of age Exclusion criteria: * Presence or history of drug hypersensitivity or allergic disease * History or presence of dermatological disorders * Fever or persistent chronic or active recurring infection requiring trea...
SAR231893 DP1 is an investigational monoclonal antibody being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial evaluating its pharmacokinetics and safety in healthy subjects. The drug is not approved for any indication and remains in early-stage clinical testing.
SAR231893 DP1 is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker SNY. The drug is an investigational monoclonal antibody currently in Phase 1 clinical development for use in healthy volunteers.
SAR231893 DP1 is in Phase 1 clinical development. A Phase 1 trial has been completed, which studied the pharmacokinetics and safety of the drug in healthy subjects. The drug is investigational and has not been approved by regulatory authorities.
SAR231893 DP1 has one completed clinical trial, identified as NCT01537640. This Phase 1 study compared the pharmacokinetics and safety of two SAR231893 (REGN668) drug products in 30 healthy subjects in the United States. The trial was randomized, double-blind, and controlled.
SAR231893 DP1 is also known as REGN668, as indicated in the clinical trial title. The Phase 1 study NCT01537640 evaluated two SAR231893 (REGN668) drug products, confirming that these names refer to the same investigational monoclonal antibody being developed by Sanofi.